title: Oral misoprostol and intracervical dinoprostone for cervical ripening and labor induction: a randomized comparison.
abstract: OBJECTIVE
  To compare efficacy, safety, and tolerance of oral misoprostol with intracervical dinoprostone for cervical ripening and labor induction.
  
  
  METHODS
  Two hundred women were randomized to receive single doses of oral misoprostol 200 microg or 0.5 mg of dinoprostone intracervically every 6 hours for a maximum four doses.
  
  
  RESULTS
  The intervals from administration of the drug to active phase of labor (11.1 hours [7-24] versus 15.8 hours [7.5-29.62], P =. 01), to delivery (14.0 hours [8.42-27.61] versus 20.2 hours [16.7-32. 8], P =.01), and to rupture of membranes (10.0 hours [4.95-24.7] versus 15.6 hours [8.2-29.2], P =.003) were significantly shorter in the misoprostol group. All those variables were not distributed normally, so results are presented as median and interquartile range. The rates of women who needed oxytocin (68% versus 52%, P =.03) and cesarean for failed induction (9% versus 1%, P =.01) were higher in the dinoprostone group.
  
  
  CONCLUSIONS
  A single dose of 200 microg oral misoprostol was more effective for cervical ripening and labor induction than 0.5 mg of dinoprostone intracervically every 6 hours, with a maximum of four doses.
authors.affiliation: Department of Obstetrics and Gynecology, University Hospital of Puerto Real, Cadiz, Spain. j.barthar@sego.es
authors.forename: J L
authors.initials: JL
authors.lastname: Bartha
authors.forename: R
authors.initials: R
authors.lastname: Comino-Delgado
authors.forename: F
authors.initials: F
authors.lastname: Garcia-Benasach
authors.forename: P
authors.initials: P
authors.lastname: Martinez-Del-Fresno
authors.forename: L J
authors.initials: LJ
authors.lastname: Moreno-Corral
mesh_terms: D000282:Administration, Intravaginal; D000284:Administration, Oral; D000328:Adult; D002584:Cervix Uteri / Q000187:drug effects*; D015232:Dinoprostone / Q000008:administration & dosage* / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D007751:Labor, Induced; D016595:Misoprostol / Q000008:administration & dosage* / Q000009:adverse effects; D010120:Oxytocics / Q000008:administration & dosage* / Q000009:adverse effects; D011247:Pregnancy; D016896:Treatment Outcome
chemical_list: D010120:Oxytocics; D016595:Misoprostol; D015232:Dinoprostone